Get the Stockscreener App
8.69
5.65%
-0.52
After Hours:
8.74
0.05
+0.58%
4 D Molecular Therapeutics Inc stock is traded at $8.69, with a volume of 1.79M.
It is down -5.65% in the last 24 hours and down -13.88% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$9.21
Open:
$9.51
24h Volume:
1.79M
Relative Volume:
1.98
Market Cap:
$496.50M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-3.2669
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-20.42%
1M Performance:
-13.88%
6M Performance:
+112.47%
1Y Performance:
+45.56%
1-Day Range:
$8.46
$9.655
1-Week Range:
$8.46
$11.81
52-Week Range:
$2.235
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
8.69 | 526.21M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
What dividend safety score for 4D Molecular Therapeutics Inc. stockJuly 2025 Action & Long-Term Investment Growth Plans - Улправда
4D Molecular posts Phase 1 trial data for cystic fibrosis drug - Seeking Alpha
4D Molecular Therapeutics Announces Positive Interim Clinical Data from 4D-710 Aerow Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - marketscreener.com
4D Molecular Therapeutics Reports Positive Interim Phase 1 Data For 4D-710 In Cystic Fibrosis - Nasdaq
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - Yahoo Finance
4DMT Announces New Employment Inducement Grants - Sahm
4D Molecular Therapeutics expands phase 3 trial enrollment - MSN
4D Molecular Therapeutics Expands Phase 3 Trial Enrollment - TipRanks
4D Molecular Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Decheng Capital LLC - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.4%Here's What Happened - MarketBeat
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
4D Molecular Therapeutics Reports Strategic Gains in Q3 2025 - MSN
How interest rate cuts could boost 4D Molecular Therapeutics Inc. stockGlobal Markets & Safe Capital Investment Plans - BỘ NỘI VỤ
4D Molecular Therapeutics taps Kristian Humer as CFO - MSN
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Transcript : 4D Molecular Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09 - marketscreener.com
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%What's Next? - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) to join Evercore Healthcare Conference fireside chat - Stock Titan
4DMT to Participate in 8th Annual Evercore Healthcare Conference - Sahm
4d Molecular Therapeutics chief legal officer sells $17k in stock - Investing.com Canada
[Form 4] 4D Molecular Therapeutics, Inc. Insider Trading Activity - Stock Titan
4D Molecular Therapeutics Executive Sells Shares - TradingView
Officer Bizily Sells 1,635 ($17.3K) Of 4D Molecular Therapeutics Inc [FDMT] - TradingView
Published on: 2025-11-19 17:30:27 - newser.com
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development - MSN
What recovery options are there for 4D Molecular Therapeutics Inc.July 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com
FDMT: 4D-150 achieves up to 92% injection reduction in wet AMD, with global phase III trials underway - TradingView
FDMT: 4D-150 gene therapy offers up to 92% injection reduction and strong safety for retinal disease - TradingView
4D Molecular Therapeutics appoints Kristian Humer as chief financial officer By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics Names Kristian Humer as CFO - MarketScreener
4D Molecular Therapeutics appoints Kristian Humer as chief financial officer - Investing.com
4D Molecular Therapeutics Appoints New Chief Financial Officer - TipRanks
4D Molecular (FDMT) Therapeutics Appoints New CFO to Drive Finan - GuruFocus
4DMT Appoints Kristian Humer as Chief Financial Officer - The Globe and Mail
4D Molecular Therapeutics Appoints New CFO - TradingView
4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer | FDMT Stock News - Quiver Quantitative
[8-K] 4D Molecular Therapeutics, Inc. Reports Material Event | FDMT SEC FilingForm 8-K - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen - MarketBeat
4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
FY2025 Earnings Forecast for FDMT Issued By Chardan Capital - MarketBeat
Can 4D Molecular Therapeutics Inc. rally from current levelsMarket Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com
4DMT (NASDAQ: FDMT) grants 45,400 RSUs to four new employees under 2025 inducement plan - Stock Titan
Leerink Partnrs Issues Pessimistic Outlook for FDMT Earnings - MarketBeat
Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position - TipRanks
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):